Driven by strong organic growth, an in-licensing agreement with Sanofi, the consolidation of Mantra, and the resolution of most legal challenges, Emcure is projected to achieve a 13% overall sales CAGR between FY2024 and FY2027. Enhanced productivity following a 20%+ expansion in field force since FY2022, along with increased utilisation of new facilities, is expected to contribute to robust EBITDA and EPS CAGRs of 18% and 29%, respectively, during the same period.
Banks unlikely to reduce deposit rates despite RBI easing
Following the latest repo rate decrease, bankers foresee only slight adjustments to deposit rates. The landscape, characterized by sluggish savings yields and elevated credit-deposit ratios,
December 8, 2025